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ABSTRACT 
 
 
Background: The Artificial Pancreas is a set system composed by a continuous 
glucose monitoring (CGM), an insulin pump and a control algorithm responsible 
for the automatic administration of insulin on the basis of the glucose 
concentration measured continuously in the interstitial fluid by CGM system.  
There are different types of CGM system. The accuracy of these devices is a 
crucial point for the correct functioning, efficacy and safety of the artificial 
pancreas. Few studies have evaluated their accuracy. 
 
Aim: To compare the accuracy of 3 glucose sensors in 2 different studies: first 
Dexcom G4 Platinum vs FreeStyle Libre, second Dexcom G5 Mobile vs 
FreeStyle Libre.  
 
Methods and results: First study: For 2 weeks, 22 subjects with type 1 diabetes 
simultaneously wore the FreeStyle Libre (FSL, Abbott, Alameda, CA) and the 
Dexcom G4 Platinum (DG4P, Dexcom, San Diego, CA). During a hospital 
phase, patients randomly received the same breakfast with standard or delayed 
& increased insulin bolus, to induce large glucose swings. Venous glucose was 
checked every 5-15 min for 6 hours. At home, patients did ≥ 4 reference finger-
sticks/day.  
During home phase, the overall MARD (mean absolute relative difference) in 
glucose levels was similar for 2 sensors: 12.9 (2.5) % for DG4P vs 13.7(3.6) for 
FSL (difference not significant [NS]). Accuracy was worse during 
hypoglycemia for both sensors, without significant difference between sensors. 
In the euglycemic range, accuracy was better for DG4P [12.0(2.4) % vs 
14.0(3.6)%, p 0.026].  
In the hospital phase, FSL performed better in the hyperglycemic range. 
Considering week one, FSLand DG4P had similar accuracy across all glucose 
ranges, but FSL had a smaller MARD when glucose was changed to >1.5 
mg/dl/min.  
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Second study: For 2 weeks 20 subjects with type 1 diabetes simultaneously 
wore the FreeStyle Libre (FSL, Abbott, Alameda, CA) and Dexcom G5M 
(DG5M, Dexcom, San Diego, CA). During a hospital phase, patients received 
the same breakfast with a delayed&increased insulin bolus to induce large 
glucose swings. Venous glucose was checked every 5-15 min for 6 hours. At 
home, patients did ≥ 4 reference finger-sticks/day.  
Twenty type 1 diabetic patients completed the study. During the at-home 
evaluation, the overall ARD was 12.3% (5.6-21.4) for the FSL and 9.8% (4.7-
18.0) for the G5M (p<0.001). ARD increased during hypoglycemia with both 
the FSL and G5M sensors and decreased during hyperglycemia. During the 
hospital phase, G5M performed better than FSL. Considering accuracy during 
different rates of change, the G5M sensor was more accurate when glycemia was 
stable and demonstrated better performance than the FSL when glucose 
increased, both slowly and rapidly. No differences in accuracy were observed 
when glucose levels decreased rapidly.  
Conclusions: DG4P performed as well as FSL, both sensors performed less well 
during hypoglycamia. During glucose swings Libre was more accurate than 
DG4P. 
The G5M sensor provides greater accuracy than the FSL sensor. 
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INTRODUCTION 
 
 
Type 1 diabetes mellitus is a condition associated with increased morbidity and 
decreased life expectancy. Since the Diabetes Control and Complications Trial 
study (DCCT) has confirmed the possibility of preventing long-term diabetes 
complications by close glycemic control [1], the goal of diabetes treatment has 
been to normalize blood glucose levels by avoiding hypoglycemia. In order to 
make this achievement easier, insulin analogues have been developed and 
insulin administration systems have been improved.  
Currently, insulin treatment strategies in type 1 diabetes includes either multiple 
daily insulin injections (MDI) or continuous subcutaneous insulin infusions with 
an insulin pump (CSII). 
It has been demonstrated that continuous subcutaneous insulin infusion has a 
favourable effect on glycated haemoglobin (HbA1c) and incidence of 
hypoglycaemia in patients with type 1 diabetes [2]. Furthermore, a meta-analysis 
of 19 trials confirmed that continuous subcutaneous insulin infusion had a 
benefit on glycaemic control in adults with type 1 diabetes compared with 
multiple daily insulin injections [3]. 
Instrumental glucose detection has also improved through the introduction of 
devices that allow continuous glucose monitoring (Continuous Glucose 
Monitoring, CGM). 
Recently, insulin delivery pumps and CGM devices have been integrated to form 
a "system" known as the Sensor-Augmented Pump (SAP), which has been more 
effective than the traditional pump in improving glycaemic control [4]. 
A new function of SAP is the automatic insulin suspension for low glucose 
values when a pre-programmed threshold value of continuous glucose 
monitoring is reached [5]. 
Despite advances in insulin formulations and technology, current treatment 
patterns very often do not allow patients  to achieve and maintain good 
glycaemic control [6].  
Artificial pancreas treatment, also referred to as closed loop glucose control, is 
an emerging treatment option which combines an insulin pump and continuos  
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glucose monitoring with a control algorithm to deliver insulin in a glucose 
responsive manner [7]. The control algorithm is the fundamental part for the 
functioning of the artificial pancreas. It determines the speed of insulin infusion 
on the basis of glucose levels. However, it should be noted that at present, the 
performance of the artificial pancreas is lower than that of the beta cell because 
the injected insulin subcutaneously acts later with respect to the insulin released 
physiologically in the portal circle, because the subcutaneous administration 
does not respect the natural hierarchy where the liver first receives the secreted 
insulin, and also for sensor - related limits, because the sensor detects the 
concentration of glucose in the interstitial fluid, rather than in the blood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Components of the artificial pancreas 
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Control algorithms 
 
The control algorithm, also called "controller" or calculation unit, plays an 
important role in the artificial pancreas, because it automatically regulates the 
infusion of insulin on the basis of glycemic values (previous, current at the time 
of reading and expected) and patient data (weight, I: CHO ratio, correction 
factor, daily insulin requirement). 
There are different types of algorithms, the main ones are: proportional –
integral-derivative (PID), model predictive of control (MPC), and fuzzy logic 
[8]. 
 
 
PID algorithms adjust insulin delivery by assessing departure from target 
glucose level (the proportional component), the area under the curve between 
measured and target glucose levels (the integral component), and the rate of 
change in the measured glucose level (the derivative component). The integral 
component can be seen as a baseline adjustment, while the changes induced by 
the derivative and proportional component in response to meals resemble the 
biphasic secretion of insulin, e.g, the dynamic phase is provided by the 
derivative component, while the static one is provided by the proportional 
component.  
 
 
Unlike PID algorithms, which can modify insulin infusion only on the basis of 
detected glucose values, MPC algorithms are "predictive" and try to determine 
the optimal insulin infusion that should be administered considering its probable 
effects on future glucose levels. 
The controller considers all of the sequences of possible future control actions 
and chooses the sequence that, according to its forecasts, can more effectively 
guarantee the achievement of the target glycaemia. 
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Other types of algorithms tested successfully in the clinic include "Fuzzy 
Logic" based algorithms where insulin administration is based on approximate 
rules, based on clinical practice [9]. 
Most algorithms contain safety modules, based on current or predicted blood 
glucose values, and on the dose of insulin administered, aimed at avoiding 
excessive insulin administration. 
 
 
Artificial pancreas types 
 
There are two types of artificial pancreas. First, there is the "hybrid" artificial 
pancreas, in which the system autonomously regulates basal insulin 
administration but requires the intervention of the patient at the time of the meal. 
In particular, it is necessary to insert the amount of carbohydrates taken in the 
meal and confirm the insulin bolus units to be dispensed. 
The second is a "fully automatic" artificial pancreas that does not require the 
intervention of the patient during the meal, but is intended to act on the effects 
of the meal in blood glucose. 
Hybrid models are predominantly used in view of the delayed effect of 
subcutaneous insulin action. These differ in pancreas mono-hormonal, which 
only administers insulin, and the bi-hormonal pancreas which administers 
insulin and glucagon. 
Glucagon administration has two purposes: to reduce the risk of hypoglycemia 
and to allow more aggressive insulin administration [10]. 
Compared to the pancreas based only on the administration of insulin, the bi- 
hormonal one involves additional problems related to the need of a second pump 
for the administration of glucagon, and the instability of the same glucagon that, 
to date, requires the replacement of the hormone, and the infusion set of 24 hours 
each. 
Long-term studies are also needed to evaluate the safety and tolerability 
associated with chronic glucagon administration. 
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Clinical evidences 
 
In the last 10 years, numerous studies have demonstrated the advantages of the 
artificial pancreas, both for glycemic control (including risk of hypoglycemia), 
and effects on patients' quality of life. Studies were conducted first in hospital, 
then in school camps or hotels under medical supervision, and then finally at the 
patient's home. 
A recent review analyzed 40 studies (1027 participants with data for 44 
comparisons). 35 of those comparisons assessed a single hormone artificial 
pancreas system, 9 assessed a dual hormone system.  
Compared with control treatment, use of the artificial pancreas was associated 
with an increased percentage of time spent in the euglycemic range (70-180 
mg/dl) over 24 hours. This effect was confirmed both in trials using artificial 
pancreas overnight, or over 24 hours (Fig 2) [7]. 
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Fig. 2 Weighted mean difference in proportion (%) of 24 hour period in near 
normoglycemic range (glucose concentration 70-180 mg/dl-3.9-10.0 mmol/L), 
artificial pancreas use versus control treatment [7]. 
 
 
Use of artificial pancreas had a favourable effect also on time spent in 
hyperglycemia (> 180 mg/dl) during 24 hours. Respect to control arm, time spent    
in hyperglycemia was shorter by about 2 hours. Time spent in hypoglycemia 
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(glucose < 70 mg/dl) during 24 hours was shorter by about 20 minutes compared 
to control treatment [7]. 
Trials with a duration of more than 8 weeks confirmed the favourable effect of 
the artificial pancreas, also by a reduction of HbA1c about 0,3% [7], 
[11],[12],[13].  
 
Kovatchev et al., in the long-term study with a single-hormone hybrid artificial 
pancreas, that used the system day and night for 6 months at home in 14 adults, 
confirmed a significant reduction of HbA1c and an increase in glycemic target 
time in patients who used the system for at least 70% of the time [14]. 
The largest non-randomized study to date has been that of Bergenstal et al. who, 
given the great test of effectiveness and safety of the system, has led to the 
approval of the first artificial pancreas by the FDA [15]. 
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Limits of the artificial pancreas 
 
One of the major limitations of artificial pancreas is related to delayed absorption 
of subcutaneous insulin, which implies difficulties in glycemic control after 
meals and during or after physical activity [16]. 
Regarding the bi-hormonal pancreas, it is necessary to consider that the long-
term effects of glucagon are unknown. In addition, a greater burden is required 
for patients to bring more devices and replace glucagon every day [17]. 
 
Finally, accuracy of CGM must be excellent, and patients must calibrate in a 
correct time, administer insulin boluses, and be ready to recognize both 
connection and technical problems. Although some studies have found a 
reduction in distress linked to diabetes [18], [19],[20], the impact of new systems 
on the psychological level remains to be defined. 
 
The artificial pancreas is a jump ahead in the treatment of diabetes. However 
there is large room for improvement regarding: 
 
 
1) Insulin administration: Further technological advancements should focus on 
improvements in insulin delivery to prolong infusion catheter use, reduce silent 
infusion catheter occlusions and accelerate insulin absorption and action  
2) Control algorithms:  Improvements of the control algorithm should include an 
increase in adaptability to the needs of the individual patient, more flexibility 
and the ability, by the machine, to decide and administer the meal boluses. 
3) CGM: A more accurate sensor is needed to increase safety of AP but at the same 
time smaller size, longer wear time and factory calibration are advised to 
improve patient’s acceptance. 
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CONTINUOUS GLUCOSE MONITORING 
 
 
The device for continuous glucose monitoring typically consists of three parts (fig. 
3): 
1. The sensor that detects glycaemia value in the interstitial fluid, 
2. A transmitter capable of processing data and transmit wirelessly, 
     3. A receiver capable of displaying processed data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 Components of CGM 
 
.  
 
 
The most currently available continuous glucose monitoring systems CGM use 
an enzymatic technology that reacts with interstitial fluid glucose molecules by 
releasing one electron to each glucose molecule, and transferring them to an 
electrode in which an electrical current is generated. The general electric current 
is proportional to the glucose concentration, and is then transmitted by a 
transmitter that connects  the sensor to a reader (wirelessly) and that displays the 
  12 
   
 12 
 
data to the patient [21].The data displayed is the value of the current glucose and 
the trend of blood glucose. Glycemic trends are shown through graphs and 
arrows that indicate which direction and speed blood glucose is changing. They 
also have security alarms, which alert the patient that the blood sugar is near 
hypo / hyperglycemic threshold (predictive alarms), or that this threshold has 
been exceeded, (threshold alarm) [21], [22], [23], [24]. 
 
 
 
Limits of CGM 
 
The use of CGM devices is strictly related to the accuracy and reliability of the 
sensor. 
 
 
 
Interstitial fluid and “lag time” 
 
CGM measures glucose in the interstitial fluid while the glucometer measures 
glucose in blood vessels at the capillary level. Because these two areas are 
physically separated, glucose takes time to move from one to another. CGM 
measures glucose in the interstitial fluid, which can delay glucose in the blood 
by 5- 15 minutes, especially when blood glucose levels change rapidly. 
 
 
 
Calibration 
 
Most CGMs require calibration with a capillary blood glucose measurement 2-
4 times a day. This process optimizes the accuracy of the data used to convert 
the raw data points into the glycaemic readings of the interstitial fluid. Although 
the purpose of blood glucose calibration is to ensure the accuracy of CGM 
readings, an error can be introduced if calibration is performed during periods of 
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rapid change that may occur after meals or after exercise. Excessively frequent 
calibration can also introduce measurement errors. [7]. 
 
The accuracy of the measurements made by continuous monitoring is greatly 
influenced by calibration. Unfortunately, there are many factors that can 
influence it. The first factor is the time at which calibration is performed, which 
should take place in maximum stability and not during glycaemic excursions. 
Second, it is a burden to the user of the sensor, since each calibration process 
requires a painful and time-consuming blood glucose (BG) test. The third factor 
concerns the possible inaccuracy of the glucose meters. Certain user mistakes 
like, not washing hands before a BG test, can lead to wrong glucose 
measurements. Some sensor systems require the user to enter the BG value 
manually for calibration, where transcription error and delayed BG entry can 
affect sensor accuracy. Despite these limitations however, the overall 
performance of the devices in use is good [25]. 
 
 
 
Accuracy 
 
A parameter frequently used to characterize the accuracy of the systems’ CGM 
is the mean absolute difference (Mean Absolute Relative Difference, MARD), 
that is the difference between values provided by the sensor and glucose values 
measured by a reference system at a given moment. 
The advantage of using this parameter consists of expressing accuracy as a single 
value [26]. Ideally, the comparison between different CGM systems would be 
performed in a head-to-head study. This is one reason why the number of head-
to-head studies using different brands or generations of CGM systems is quite 
limited. [26]. 
The accuracy of the different systems has changed over time. Currently, they are 
on market devices with a total MARD <15% compared to real values. The 
evolution in the last 15 years of CGM accuracy, calculated as MARD of some 
of the most important CGM used, is shown in figure 4 [27]. 
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Fig.4 The accuracy timeline of CGM sensors over the last 15 years.[27]. 
 
 
 
Most systems take one to two days for optimal performance (= lower MARD 
values) to obtain the conditions of sufficient stability of the sensor in the 
subcutaneous tissue. In fact, during the first days, the local trauma of the 
insertion can have an impact on the results of the measurements [26]. 
Another method for assessing the accuracy of CMG is the use of ARD. The 
absolute relative deviation (ARD) is the absolute relative difference between the 
reference concentration (capillary blood sugar or YSI) and the value of the 
CGM.  
ARD is less dependent on anomalous values and therefore tends to be lower than 
MARD. 
The MARD is easy to calculate and interpret, however, it does not allow any 
distinction between positive and negative errors or between systematic and 
random errors [28]. 
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An additional analytical tool used to evaluate the accuracy of the data provided 
by CGM systems is represented by the modified version of the Clarke error grid, 
subsequently modified by Parkes (CG-EGA). This tool evaluates the clinical 
implications that derive from errors in blood glucose measurements; in the case 
of the sensor. It expresses the probability of making a correct therapeutic 
decision based on the value it finds. 
 
 
The scatterplot that appears in the grid is the result of the coupling of the values 
measured by the CGM with the values provided by the reference system at a 
precise moment. The grid is composed of different areas, which have a different 
clinical meaning, i.e.,  the data that fall in zone A are considered accurate, those 
that fall in zone B are considered still acceptable, and the values distributed in 
the C-E areas are considered wrong with differing degrees of severity (Figure 
5). According to ISO15197--the 2013 standards to consider a glucometer 
accurate--99% of the results it provides should be included in the A + B areas of 
the Consensus Error Grid [29], [30]. 
 
 
. 
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Fig. 5 Representations of the modified version of the Clarke error grid. 
 
 
The glucose values measured by the reference system are placed on the abscissa, with 
values from 0 to 400 mg / dl (0-30 mmol / L). In the ordinate the glucose values measured 
by the systems CGM. The combinations of the two values are distributed in zones A, B, 
C, D and E of the grid, which represent a different clinical significance [29]. 
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Real time CGM types 
 
Actually in Italy the most used real time CGM are: Dexcom G4 Platinum, 
Dexcom G5 Mobile, Medtronic Enlite. Accuracy of Dexcom G4 Platinum 
(DG4P) has been studied in different trials. Van Beers et al. demonstrated a 
MARD about 13% respect to Yellow Springs glucose analyzer (YSI Inc, Yellow 
Springs, OH, which has an accuracy comparable to that of the dosages performed 
in laboratory). The accuracy was similar also when comparing DG4P with 
capillary blood glucose determined by glucometer (SMBG) [31]. This result was 
in line with other studies [32], [33], [34].  
Enlite sensor is the fourth-generation Medtroinc sensor (Guardian 3). 
Christiansen M. et al. recently demonstrated that a MARD  between 9.6% – 
9.0%, whether the sensor is located in the abdomen or the arm, provided accurate 
glucose readings when compared with YSI reference [35].  
Dexcom G5M is a new generation of sensor with a new algorithm, used in a 
modified Dexcom G4 Platinum receiver. In order to improve the accuracy of the 
Dexcom G4, the creation of an "intelligent" signal processing algorithm has been 
designed. The new signal processing code was released by Dexcom Inc. entitled  
"505 software," which allowed  reduction of the MARD of the G4 Platinum from 
13% to 9% [32], [36], [37]. 
 
In particular studies demonstrated in adults, there was an overall MARD of 9%, 
while 10% in paediatrics. The two studies observed a detection rate of 
hypoglycemia, at an alert level of 80 mg/dL, of 90% and 91%, respectively 
[38][37]. % (MARD) 40-40/d  
In December 2016, the US Food and Drug Administration approved the Dexcom 
G5M for non-adjunctive insulin dosing [39].  
These algorithms are particularly important for the artificial pancreas [40] in 
which the rapid detection of CGM and insulin pump abnormalities is 
fundamental for patient safety, avoiding an incorrect calculation of the insulin 
dosage to be injected.  
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Flash Glucose Monitoring System 
 
 
Flash Glucose Monitoring (FGM) system (FreeStyle LIbre FSL) is a different 
system of continuous glucose monitoring, which entered on market in 2014 (Fig. 
6). 
Unlike conventional real time CGM systems, FGM is pre-calibrated in factory 
so it does not require calibration, but does not provide alarms. 
The system includes a sensor that can be used for up to 14 days to continuously 
measure glucose levels at 1 minute intervals, storing data for the last 8 hours 
[41]. 
By performing a quick sensor scan, the patient can view current blood glucose 
levels on a reader, and a graph showing glucose trend. 
A study conducted on seventy-two subjects affected by DMT1 or DMT2 
demonstrated the accuracy of the sensor, remaining stable over 14 days and not  
influenced by BMI, age and other characteristics of patients. There, Global 
MARD, compared to the reference values of the capillary blood glucose, was 
equal at 11.4% [42]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Freestyle Libre System Flash Glucose Monitoring (FSL)  
 
  19 
   
 19 
 
Implantable CGM systems 
 
A new implantable subcutaneous CGM system (Ever-sense CGM system, 
Senseonics, Inc., Germantown, MD) has recently been put on the market. The 
Eversense sensor has a duration of 90 days, compared to the traditional 7 days 
of CGM real time. The transmitter can be removed at any time without the need 
to replace the sensor. The alarms, hypoglycemic and hyperglycemic 
notifications are provided on a mobile device and on vibrational alerts on the 
body from the transmitter. The CGM system consists of an implantable 
fluorescence-based sensor, a transmitter; and an app that displays data on a 
mobile device. 
The sensor is activated to measure interstitial fluid glucose every 5 minutes when 
it receives radiofrequency energy from the transmitter.  
The sensor contains a polymer. This polymer is fluorescent and uses a 
completely reversible bond between glucose and the attached molecular 
complex to detect glucose concentrations (Fig. 7). 
The association of glucose determines an increase in fluorescence intensity, 
measured by the optical system of the sensor [43]. 
A non randomized, blinded, prospective, single-arm, multi-center study 
(PRECISE) evaluated the accuracy and safety of the Eversense CGM system 
among adult participants with T1D and T2D, and demonstrated an overall 
MARD value against reference glucose values of 8.8%[43].  
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Fig.7 Eversense  system. 
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PURPOSE OF THE THESIS 
 
 
Accuracy is the most important feature in a continuous glucose monitoring device. 
Artificial pancreas requires correct data, correct decisions require accurate 
information, and accurate information requires accurate monitoring devices.  
Considering the limits of CGM and the importance of the precision of the data for 
the proper functioning of the artificial pancreas, our studies wanted to compare the 
accuracy of the main devices for monitoring in glucose in order to evaluate their 
possible use in the artificial pancreas. 
We concluded 2 studies. The first compared the accuracy of Dexcom G4 Paltinum 
compared to FreeStyle Libre (FSL) while the second compared Dexcom G5 Mobile 
with respect to FSL. 
The comparison took place both in real life conditions and in experimental 
conditions of induction of wide glycemic excursions. 
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FIRST STUDY 
Dexcom G4 Platinum versus Free Style Libre (flash glucose monitoring) 
 
 
Materials and Methods 
 
It is a monocentric, open-label, randomized, cross-over study performed at the 
clinical research center of the of Padova University between April and 
November 2016. 
 
Participants were 18 years or older, had type 1 diabetes from ≥ 1 year and were 
treated with CSII or MDI.  
 
Inclusion criteria: 
- Age over 18 years; 
- Type 1 diabetes mellitus (diagnosed according to the criteria of the WHO) for 
at least 1 year; 
- Body Mass Index (BMI) <35 kg / m²; 
- Availability to wear the device and to comply with the study protocol during 
the entire duration of the same; 
- Signing of informed consent before any procedure related to study. 
 
Exclusion criteria: 
- Pregnancy, breastfeeding, intention to undertake a pregnancy or refusal to use 
contraceptive methods during the duration of the study (for subjects, female); 
- Known allergies to patches or skin disinfectants used during the study; 
- Skin lesions, irritations, redness, edema in possible sites, application of sensors; 
- Donations of whole blood in the 3 months preceding the study; 
- Use of drugs that could have interfered with glucose metabolism (such as 
steroids or paracetamol) unless they were chronic therapies whose dosage had 
remained stable in the last 3 months and was expected to remain stable during 
the study period; 
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- Serious medical or psychological conditions in the opinion of medical 
personnel could have compromised patient safety during participation in the 
study; 
- Participation in other clinical studies during the same period; 
- Known disorders of the adrenal glands, pancreatic tumors or insulinomas; 
- Patient's inability to comply with the study procedures. 
 
The study was registered in ClinicalTrials.gov (NCT02734745), approved by the 
institutional ethics review board, and done according to the Declaration of 
Helsinki.  
 
 
 
Devices 
 
During the study, patients used simultaneously two devices: FreeStyle Libre 
(FSL) and Dexcom G4 Platinum (DG4P) for 14 days. 
 
Freestyle Libre system is composed by a sensor and a receiver. The sensor has 
to be inserted subcutaneously posteriorly on the upper part of the arm. The sensor 
is composed by a catheter placed in the subcutis, containing the glucose-oxidase 
enzyme, measures the concentration of glucose in the subcutaneously every 
minute. This is connected to a round disk applied on the back of the upper arm. 
By scanning the reader on the sensor, patients can view the current glucose 
value, the glycemic profile of the previous 8 hours and a trend arrow indicating 
the direction to which it is going in the blood glucose and the rate of variation of 
the same. The duration of the device is 14 days.  
 
Dexcom G4 Platinum is composed by a sensor inserted under the skin (usually 
in the abdomen) and a reader that permit to visualize real time glycaemic values. 
This system requires calibration twice a day. The device is approved for a 
maximum use of 7 days (manufacturer specified lifetime: MSL). To reduce the 
costs and the inconvenience of changing it, it is possible to extend the period of 
use of the device by another 7 days, reactivating it as if a new sensor was 
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inserted. De Salvo et al. have shown that accuracy is similar on days 1-7 and 8-
14 of use [44]. 
 
 
 
 
YSI 2300 STAT Plus ™ Glucose Analyzer 
 
The Yellow Springs glucose analyzer (YSI Inc., Yellow Springs, OH) is a device 
able to determine the plasma glucose values with an accuracy comparable to that 
of assays performed in the laboratory (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 Yellow Springs glucose analyzer 
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DESIGN OF THE STUDY 
 
Patients were trained by study personal on the use of the two systems.  
At the first visit, the 2 sensors were placed, at the same time, on the back of the 
arm (Freestyle Libre) and in the abdominal region (DG4P) respectively. 
The study took place both at the patient's home for 14 days in total, and in a 
hospital environment for 2 visits scheduled at 3-5 days and 9-11 days from the 
positioning of the sensors. During these visits, each patient received a standard 
breakfast, in one case preceded by a regular insulin bolus, in the other, the insulin 
bolus was administered late and increased to cause a mild hyperglycemia 
followed by hypoglycemia. The order in which one type of bolus was performed 
rather than another was chosen on the basis of a 1: 1 randomization. 
The sensors data during home phase were compared with capillary blood finger 
stick measurements (SMBG), while during hospital phase sensor data were 
compared with venous blood glucose (YSI). 
 
 
 
Home phase 
At home, patients performed capillary blood glucose (SMBG) at least four times 
per day (before meals and at bed-time) using the BG meter built into the hand-
held reader of the flash glucose monitoring system, and immediately after each 
BG test. Patients were instructed to calibrate the DG4P against capillary blood 
finger stick measurements. After 7 days to access accuracy patients began a 
second 7-day session over the manufacturer lifetime specified (MLS). In case of 
sensor failure, loss of signal, skin issues or any problem the sensor was 
substituted.  After 14 days, data of the two sensors were downloaded.  
 
 
 
Hospital Phase 
Hospital phase was divided into 2 visits. 
In one occasion patients arrived fasting at the hospital at 7.45 am. After DG4P 
calibration, a venous cannula needle was placed to perform blood samples for 
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measurement of venous glucose values, maintained by means of infusion of 
physiological solution. Blood samples started at 8:00 am. Glucose concentration 
was measured using the YSI 2300 STAT instrument PLUSTM glucose and 
lactate analyzer (YSI Inc., Yellow Springs, OH). At 8:15, patients had a standard 
breakfast. The insulin dose administered before breakfast was calculated on the 
basis of the carbohydrate-to-insulin ratio of the patient and the adding of a 
correction bolus in case fasting plasma glucose was > 100 mg / dl (> 5.6 mmol / 
L). Blood samples were performed every 15 minutes from 8:00 to 11:00 (period 
in which the glycemic variability tied to the meal is greater), and then every 30 
minutes in the next 3 hours of study. During hypoglycemia were performed 
every 5 minutes. The patient was also asked to perform capillary blood glucose 
detection before breakfast and then every hour until the end of the 6 hours of 
study. Capillary blood glucose measurement and detection of glucose 
measurements of the two devices were obtained immediately after or 
simultaneously to the measurement of blood samples. Patients left the hospital 
at 2 pm. 
 
 
 
Fig. 9 flow chart of the visit 
 
 
The other visit took place 3-6 days after the previous one. As for this phase, the 
patient went fasting at hospital at 7.50 hours, and after positioning a cannula 
needle for blood samples, received the standard breakfast at 8.15 am. The insulin 
dose in this occasion was doubled and administered 30 minutes after breakfast 
(increased&delayed bolus), to induce an early post-meal hyperglycemia 
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followed by a drop in blood glucose, adjusted to induce the maximum post-
prandial glycemic excursion (linked to delay in bolus administration) followed 
by a mild controlled hypoglycemic phase (linked to the increase in the size of 
the bolus). Blood samples started at 8.00am and were run every 15 minutes until 
9.00am, then every 10 for the next 3 hours, in the period of maximum glycemic 
excursion. From 12.00 to 13.00 the frequency was reduced to a withdrawal every 
15 minutes, and then one each 30 minutes until the end of the study (Figure 9). 
If hypoglycemia was reached 30 glucose grams were given per os when 
glycaemia ≤ 54 mg / dl (< 3 mmmol/l), or first at the discretion of the medical 
staff. The patient was required measuring capillary blood sugar before breakfast, 
every hour until the end of study, and ongoing hypoglycemia immediately before 
administration of 15 grams of glucose. At the same time of each sample the 
glucose value was detected measured by the sensors, as well as at the time of 
hypoglyaemic correction. At the end of the visit, the patient returned home, 
continuing with the use of the devices. 
The two hospital visits were crossovers, for testing whether the accuracy of the 
FSL and DG4P systems, during the induction of one moderate hypo-
hyperglycemia remained the same regardless of time elapsed, since the day the 
sensors were inserted. 
After 14 days, patients went back to the hospital for sensor removal, return of 
devices and download data. 
 
 
Fig. 9 flow chart of the visit 
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Evaluation of sensor’s accuracy 
 
Glucose values measured by the two systems for continuous monitoring were 
matched with the values provided by the venous blood sample or capillary blood 
and accuracy was expressed as absolute average difference (MARD) between 
the sensor values and the reference values. The values provided by glucose 
plasma were used as reference values during the hospital phase, while capillary 
blood glucose values were used as a reference during the home phase. 
MARD analysis was considered separately for breakfast with increased and 
delayed bolus, compared to breakfast with normal insulin bolus, and for the first 
and second week of sensor use. 
MARD was calculated for all comparisons, over the entire glycemic range and 
divided into different ranges: hypoglycemia (<3.9 mmol / L, <70 mg / dl), 
hyperglycemia (> 10 mmol / L,> 180 mg / dl) and euglycemia (3.9 -10 mmol / 
L, 70-180 mg / dl). 
In addition, the accuracy of the sensor was also corrected by calculating both the 
percentage of data points in zones A and A + B of the Clarke Error Grid (CEG) 
and the percentage of values that met the ISO 15197: 2013 criteria (percentage 
of sensor data within ± Reference value of 15% for glucose concentrations ≥ 5.6 
mmol / L (100 mg / dl) and within ± 0.8 mmol / L (15 mg / dl) of the reference 
value for glucose concentrations <5.6 mmol / l (100 mg / dl). 
For the hospital phases MARD was also calculated by dividing the BG values 
into five groups based on the rate of variation (ROC), calculated as the first order 
difference between the current and previous sample, divided by the temporal 
distance between the two. The five ROC intervals were:> +1.5 mg / dl / min (> 
0.08 mmol / L), between +1.5 and +0.5 mg / dl / min (+0.08 and +0, 03 mmol / 
L), between -0.5 and +0.5 mg / dl / min (-0.03 mmol / L and + 0.03 mmol / L), 
between -0.5 and -1.5 mg / dl / min (-0.03 mmol / l and -0.08 mmol / L) and <-
1.5 mg / dl / min (<- 0.08 mmol / L). The accuracy of the sensor, based on ROC 
values was measured considering all hospital sessions (with and without induced 
hypoglycaemia) and separating the first of the two visits. 
During the home phase, the MARD analysis was also performed, comparing day 
1 (day of insertion of Libre), compared to all other days, days 1 and 8 compared 
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to all other days, week 1 vs week 2, and finally grouping 1-10 days vs. 11-14 
days. Data are presented as mean ± standard deviation. 
 
 
 
Statistical analysis 
 
For descriptive statistics univariate analyses were used. To compare the 
normally and abnormally distributed values T-test and Wilcoxon tests were used. 
The averages of more than two groups were compared by analysis of variance 
(ANOVA). All comparisons were conducted with level of significance α = 0.05 
using two-tailed tests. All statistical evaluations were made using MATLAB, 
and in particular, the Statistics Toolbox (Release 2016a, The MathWorks, Inc., 
Natick, Massachusetts, United States). 
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RESULTS 
 
Twenty-four patients with type 1 diabetes were enrolled in the study. One patient 
was excluded from analysis as home data could not be uploaded. One patient left 
the study for poor devices acceptance. 
Twenty-two patients completed the study. Patient’s ages were 36.3±12.9 years 
old (mean ±SD), diabetes duration 18.9±11.1 years, HbA1c 7.3±0.75% 
(56.7±8.19 mmol/mol). Others characteristic are described in table 1. 
 
 
Number 
of 
patients 
Sex Age 
(mean + 
SD) 
BMI 
(Kg/m2+SD) 
HbA1c 
(% + SD) 
Duration 
diabetes) 
(years 
n. 
MDI 
n. 
CSII 
22 13 F+ 9M 36.3±12.9 23.5±2.7 7.3±0.75 18.9±11.1 12 10 
 
Table 1: Patients characteristics 
 
 
 
Home phase 
 
During home phase, no significant difference in overall accuracy between 
FreeStyle Libre and DG4P were noted [overall MARD 13.7 (3.6) and 12.9 (2.5), 
p = 0.392)] (fig 10).  
The two sensors had similar accuracy in the hypoglycemic and hyperglycemic 
range, DG4P showed better performance in the euglycemic range (Table 2). 
Both systems showed worse accuracy in the hypoglycemic range. 
FSL accuracy was worse in days 11-14 compared to days 1-10 (MARD 12.6 ± 
6.0 % days 1-10 vs 15.0± 8.2% days 11-14, p = 0.006). Regarding DG4P, 
accuracy was worse on day 1 and 8 (MARD 14.5 ± 7.1 % vs 11.7±7.4 %, p = 
0.015) (Table 3 , Fig. 10). 
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Glucose profile MARD (%) at home 
 1-14 days 1-7 days 8-14 days 
 FSL DG4P Data pairs P FSL DG4P Data 
pairs 
p FSL DG4P Data 
Pairs 
P 
Overall 13.7±3.6 12.9±2.5 2251 0.392 13.0±3.7 12.5±4.1 1264 0.655 14.6±4.9 13.4±3.2 987 0.219 
Hypoglycaemia 
( < 3.9 mmol/mol or 
< 70mg/dl)  
19.5±13.4 24.3±12.1 233 0.198 18.9±14.9 23.2±17.3 119 0.288 22.3±17.2 25.4±16.8 114 0.164 
Euglycaemia 
 (3.9-10 mmol/l or 
70-180 mg/dl )  
14.0±3.6 12.0±2.4 1416 0.026 13.6±4.0 11.7±3.5 817 0.088 14.8±4.9 13.2±5.0 599 0.140 
Hyperglycaemia 
( > 10 mmol/l or > 
180 mg/dl) 
10.5±3.4 10.8±3.1 602 0.778 9.9±3.5 10.3±4.2 328 0.740 11.4±5.2 11.5±3.0 274 0.938 
 
*MARD is defined as [(sensor glucose –reference blood glucose)/reference blood glucose] expressed as a 
percentage. 
 
Table 2. Mean absolute relative difference (MARD*) between FreeStyle Libre or Dexcom G4 Platinum 
glucose readings and capillary glucose reference concentration in patients with type 1 diabetes at home[45]. 
 
 
 
Figure 10.  Mean absolute relative difference (MARD) per day ± 95% confidence interval for  FreeStyle 
Libre or Dexcom G4 Platinum  [45] 
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MARD  Libre P value DG4P P value 
OVERALL 13.7 ± 3.6   12.9 ± 2.5   
D
A
Y
S 
1 15.3 ± 7.7 
0.094   
14.8 ± 6.6 
0.071 
2 12.9 ± 6.1 13.2 ± 5.1 
3 12.4 ± 6.8 12.8 ± 7.1 
4 13.4 ± 6.2 11.7 ± 7.4 
5 10.9 ± 4.4 9.7 ± 6.8 
6 12.1 ± 6.9 9.2 ± 4.1 
7 11.1 ± 4.5 9.4 ± 4.7 
8 13.1 ± 5.7 14.2 ± 7.6 
9 12.0 ± 5.7 12.0 ± 10. 
10 12.7 ± 5.6 11.6 ± 4.6 
11 16.6 ± 9.0 12.9 ± 8.1 
12 16.8 ± 11.1 11.1 ± 7.8 
13 13.1 ± 6.4 15.1 ± 12. 
14 13.4 ± 4.4 13.6 ± 8.4 
1-7 13.0 ± 3.7 
0.080 
12.5 ± 4.1 
0.092 
8-14 14.6 ± 4.9 13.4 ± 3.2 
1 15.3 ± 7.7 
0.117 
14.8 ± 6.6 
0.060 
2-14 13.1 ± 6.6 11.9 ± 7.5 
1+8 14.2 ± 6.8 
0.272 
14.5 ± 7.1 
0.015 
2-7 + 9-14 13.1 ± 6.7 11.7 ± 7.4 
1-10 12.6 ± 6.0 
0.006 
11.9 ± 6.8 
0.171 
11-14 15.0 ± 8.2 13.2 ± 9.1 
 
Table 3. Mean absolute relative difference (MARD) of FreeStyle Libre and Dexcom G4 
Platinum compared with capillary reference in patients with type 1 diabetes at home for 
different groups of days[45]. 
 
 
 
 
Hospital phase 
 
Ten patients performed the delayed and increased insulin bolus test during 
breakfast the first week, and the other twelve during the second week of sensor 
use. 
During breakfast with delayed and increased bolus, FSL demonstrated better 
accuracy with an overall MARD less than DG4P (14.9 ± 5.5 vs 18.1 ± 8.1), 
although the difference was not statistically significant (p = 0.062). During 
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hyperglycemia, Libre showed a lower MARD compared to DG4P (10.2 ± 4.9 vs 
14.5 ± 6.1, p <0.031). 
Even during breakfast with a standard insulin bolus, FSL had a lower MARD 
compared to DG4P in the hyperglycemic range (> 10 mmol / l> 180 mg / dl) 
(Table 4). 
The two sensors demonstrated similar accuracy during the first week of use, 
while FSL showed greater accuracy compared to DG4P during the second week 
both total and in the hyperglycemia interval (table 5). 
 
 
Glucose profile Breakfast with standard insulin bolus  Breakfast with delayed&increased insulin bolus 
 FSL DG4P Data Pairs P FSL DG4P Data 
pairs 
P 
Overall 10.9±4.1 13.1±4.6 424 0.055 14.9±5.5 18.1±8.1 710 0.062 
Hypoglycaemia 
(< 3.9 mmol/mol or < 
70 mg/dl ) 
10.8±6.9 12.9±11.9 9 
 
0.824 21.7±14.4 27.3±22.9 87 0.148 
Euglycaemia 
 ( 3.9-10 mmol/l or 70-
180 mg/dl)  
13.3±4.9 13.7±6.7 245 
 
0.894 17.3±6.9 18.5±7.2 362 0.421 
Hyperglycaemia 
( > 10 mmol/l or > 180 
mg/dl ) 
7.8±4.5 11.2±5.1 170 
 
0.010 10.2±4.9 14.5±6.1 261 0.031 
 
* MARD is defined as [(sensor glucose –reference blood glucose)/reference blood glucose] 
expressed as a percentage. 
 
Table 4. Mean absolute relative difference (MARD) between FreeStyle Libre or Dexcom G4 
Platinum glucose readings and reference glucose concentration in venous blood in patients 
with type 1 diabetes receiving a breakfast with standard or delayed&increased insulin bolus 
[45].  
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 MARD vs YSI in the first week of the 
study (Days 1-7) 
MARD vs YSI in the second week of 
the study (Days 8-14) 
 
 FSL DG4P Data 
pairs 
p-
value 
FSL DG4P Data 
Pairs 
p-
value 
Overall 
 
13.3±5.8 15.7±7.4 590 0.143 12.5±4.5 15.6±6.7 544 0.029 
Hypoglycaemia 
(< 3.9 mmol/mol 
or 
<70 mg/dl) 
 
24.6±18.6 31-5±26.6 44 0.258 15.8±6.7 18.6±15.0 52 0.404 
Euglycaemia [3.9-
10 mmol/l or 70-
180 mg/dl)]  
 
15.3±7.3 16.1±8.3 325 0.804 15.3±5.1 16.2±6.1 304 0.293 
Hyperglycaemia 
[> 10 mmol/l or 
>180 mg/dl)] 
 
9.3±4.8 12.0±4.2 221 0.075 8.8±5.0 14.1±7.2 220 0.008 
 
Table 5. Mean absolute relative difference (MARD)   of   FreeStyle Libre and Dexcom G4 
Platinum compared with venous reference in patients with type 1 diabetes in hospital during 
the first and second week of the study [45]. 
  
  35 
   
 35 
 
Clark Error Grid Analysis  
Regarding Clarke Error Grid Analysis, there was no difference in the systems’ 
clinical performance with most values distributed in the clinically acceptable 
error zones (A+B), (Fig.11, Tab 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11 Clarke Error Grid Analysis for FreeStyle Libre (grey dots) and Dexcom G4 
Platinum (black dots) vs capillary measurements on the whole study period (14 
days)[45]. 
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Fig. 12 Clarke Error Grid Analysis for FreeStyle Libre (grey dots) and Dexcom G4 Platinum 
(black dots) vs venous measurements during the clinic phase with hypoglycaemia induction [45]. 
 
 
 
 
% of data pairs in Zone 
 CEGA 
A 
CEGA 
B 
CEGA 
A+B 
ISO 
15197:2013 
 
Home Phase (glucose sensors compared with self-monitoring 
blood glucose). 
FSL 80.9 17.0 97.9 70.2 
DG4P 80.8 15.4 96.3 73.5 
CRC phase (glucose sensors compared with venous blood 
glucose). Breakfast with standard insulin bolus 
FSL 85.8 14.2 100.0 74.1 
DG4P 83.9 15.8 99.7 65.0 
CRC phase (glucose sensors compared with venous blood 
glucose). Breakfast with delayed and increased insulin bolus 
FSL 78.9 19.5 98.2 69.5 
DG4P 67.1 28.4 95.5 57.0 
 
 
* Performance of the sensor stability was assessed by calculating the percentage of system 
readings within ±0.83 mmol/L or ±15 mg/dl (for values <100mg/dl or  <5.55 mmol/L ) or 
±15% (for values ≥100mg/dl or >5.55 mmol/L). 
 
Table 6. Distribution of data  pairs in Clarke Error Grid Analysis (CEGA) zones  and ISO 
15197:2013 standards during  home or hospital phase of the study[45].   
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Regarding the accuracy analysis during different rates of glucose 
concentration, this was only possible in the hospital phase where the YSI 
values were available. No significant difference in sensor accuracy was found 
when glucose was stable (-0.5 <ROC <0.5 mg / dl / min or -0.03 <ROC <0.03 
mmol / L), whereas for rapid glucose variations FSL was more precise than 
DG4P (Tab. 7). 
However, we must remember that DG4P was used over MSL, therefore 
evaluating the accuracy of DG4P within MSL (1 week), and comparing it with 
the first week of FSL, there was no significant difference between the two 
systems except the best performance of FSL during glucose changes> 1.5 mg / 
dl / min (> 0.08 mmol / L). 
 
  
 
 
Rate of 
change 
(mg/dl/min)  
MARD-All YSI sessions  
(both with and without 
hypoglycemia induced) 
MARD-YSI session during the 
first week of the study 
  
MARD – YSI session during the 
second week of the study  
 
 1-14 days 1-7 days 8-14 days 
 FSL DG4P Data 
pairs 
P FSL DG4P Data 
pairs 
P FSL DG4P Data 
Pairs 
P 
ROC>1.5 17.0 
(14.7) 
23.0 
(14.1) 
1700 <0.001 16.8 
(12.0) 
20.7 
(14.8) 
99 0.07 17.8 
(14.0) 
25.5 
(12.2) 
71 <0.001 0.5<ROC≤1.5 12.4 
(11.0) 
15.2(12.7) 127 0.010 13.8 
(12.0) 
15.8 
(13.1) 
72 0.362 10.6 (9.0) 14.6 
(12.1) 
55 0.019 
-0.5≤ROC≤0.5 12.9 
(11.0) 
14.0 
(13.7) 
321 0.083 13.5 
(12.6) 
13.0 
(15.3) 
177 0.702 12.6 (8.5) 14.6 
(10.9) 
144 0.039 
-1.5≤ROC<-0.5 11.8 (9.9) 14.3 
(13.6) 
337 <0.001 12.7 
(10.6) 
13.2 
(14.5) 
180 0.684 10.8 (9.0) 14.9 
(12.7) 
157 <0.001 
ROC<-1.5 13.2 
(13.3) 
16.9 
(18.9) 
172 <0.001 
 
13.7 
(13.6) 
18.3 
(19.4) 
106 0.049 12.4 
(13.6) 
13.9 
(18.7) 
66 0.248 
 
Table 7. Mean absolute relative difference (MARD) between FreeStyle Libre or Dexcom 
G4 Platinum  readings and reference venous blood glucose according to different rates of 
change of glucose concentration[45].  
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Safety and adverse events  
The average duration of the sensor was found for DG4P of 13.45 days for FSL 
of 13.5. No sensor failures that require removal or infection at the insertion site 
have been reported. 
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SECOND STUDY 
Dexcom G5 versus Free Style Libre (flash glucose monitoring) 
 
 
Materials and Methods 
 
It is a monocentric, open-label, randomized, cross-over, performed study at the 
clinical research center of the Complex Disease Operative Unit of the 
Metabolism of the University of Padova between February and September 2017. 
 
Participants were 18 years or older, had type 1 diabetes from ≥ 1 year and were 
treated with CSII or MDI.  
 
Inclusion and exclusion criteria were the same as the previous study. 
The study was registered in ClinicalTrials.gov (NCT02734745), approved by the 
institutional ethics review board and done according the Declaration of Helsinki. 
 
 
 
Devices 
 
During the study, patients were trained by study personnel on the use of the two 
devices, simultaneously wore the two devices, Freestyle Libre and Dexcom 
G5M (DG5M), for 14 days. FreeStyle Libre is the same sensor of the previous 
study. 
Dexcom G5M is similar to Dexcom G4 (previouolsy described) eccept for a 
new more accurate algorithm (software 505). With Dexcom G5M patient can 
also use his/her personal smartphone instead of a receiver to view glucose data 
and calibrate the device. 
 
The device is approved for a maximum use of 7 days. Patients changes sensor 
after 7 days according to M manufacturer specified lifetime (MLS). 
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DESIGN OF THE STUDY 
 
The two sensors were placed, at the same time, on the part, back of the arm 
(FSL), respectively, and in the abdominal region (DG5M). 
 
The study took place both at the patient's home for 14 days in total, and in a 
hospital environment in 1 visit scheduled 3-5 days from the positioning of the 
sensors. During these visits, each patient received standard breakfast. Insulin 
bolus was administered late and increased to cause a mild hyperglycemia 
followed by hypoglycemia.  
At-home sensor readings were matched with capillary glucose values (≥4/day), 
acquired by Accu-Chek Aviva Connect (Roche Diagnostics, Mannheim, 
Germany). Hospital phase readings were matched with venous glucose values 
that were measured every 5-15 min with the YSI 2300 STAT PLUSTM glucose 
and lactate analyzer (YSI Inc. Yellow Springs, OH). 
 
 
 
Home phase 
At home, patients performed capillary blood glucose (SMBG) at least four times 
per day (before meals and at bed-time) to confirm the readings sensor scan. 
Patients calibrated the DG5M according to manufactures’ specifications against 
capillary blood finger stick measurements. After 7 days, patients changed 
sensors and began a second 7-day session. In case of sensor failure, loss of 
signal, skin issues or accidental dislodgment, the sensor was substituted.  After 
14 days, data from FSL and DG5M were downloaded.  
 
 
 
 
Hospital phase 
Hospital phase took place 3-5 days after the previous one. As for this phase, the 
patient went to fast at the research center at hours 7.50, and after positioning a 
cannula needle for blood samples, received the standard breakfast at 8.15 am. 
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The insulin dose was doubled and administered 30 minutes after breakfast 
(increased&delayed bolus), to induce an early post-meal hyperglycemia, 
followed by a drop in blood glucose. Blood samples started at 8.00 am and they 
were run every 15 minutes until 9.00 am, then every 10 minutes until 12.00 am, 
for a period of maximum glycemic excursion. From 12.00 to 13.00 the frequency 
of withdrawals was reduced to a withdrawal every 15 minutes, and then one each 
30 minutes until the end of the study (Figure 9). 30 grams were given glucose 
per os at the time when the blood sugar reached values ≤ 70 mg / dl or first, at 
the discretion of the medical staff. One was required for the patient measuring 
capillary blood sugar before breakfast, every hour until the end of study and 
ongoing hypoglycemia immediately before administration of 30 grams of 
glucose. At the same time of each sample the glucose value was measured by 
the sensors and glucometer. At the end of the visit, the patient returned home, 
continuing with the use of the devices. 
 
After 14 days, patients went back to the hospital for sensor removal, return of 
devices and to download data. 
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Evaluation of sensor’s accuracy 
 
Accuracy was evaluated using the absolute difference (AD), absolute relative 
difference (ARD), percentage of data matching the ISO 15197:2013 standard, 
and percentage of data points in zones A and A+B of the Clarke Error Grid 
(CEG). We also evaluated accuracy by categorizing blood glucose reference 
values into five groups, based on glucose rate of change (ROC), calculated as 
the first-order difference between the current and the previous sample, divided 
by the time distance between the two.  
 
 
 
 
Statistical analysis 
 
To test normally and abnormally distributed values a Lilliefors test was used. A 
t-test was used for normally distributed data. Wilcoxon signed-rank test was 
used for non-normally distributed data. All comparisons were conducted with 
level of significance α = 0.05 using two-tailed tests. Data are presented as 
mean (standard deviation) or median [25th-75th] percentile. 
All statistical evaluations were made using MATLAB, and in particular, the 
Statistics Toolbox (Release 2016a, The MathWorks, Inc., Natick, 
Massachusetts, United States). 
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RESULTS 
 
Twentyone patients were enrolled. One of them was excluded from the analysis 
due to impossibility to download data. Twenty patients (10 females, 10 males) 
of average age 39.0 ± 13.8 years, with average disease duration 23.3 ± 11.7 
years, mean HbA1c 7.4 ± 0.7% (57.6 ± 7.9 mmol / mol) concluded the study. 
 
 
 
Home phase 
 
During the home phase, the general ARD was better for DGM5 compared to 
FSL, respectively 9.8 (4.7-18.0) % for the DG5M and 12.3 (5.6-21.4) % for FSL 
(p <0.001). In the hypoglycemic range, accuracy was worse for both systems 
with increased ARD (13.7 [7.4-23.9] % for FSL and 14.0 [7.7 -23.2] % for 
DG5M, p = 0.8468). In the hyperglyaemia range, however, the accuracy was 
better for DG5M compared to FSL (10.2 [4.5-16.8% and 8.5 [4.3-13.9%], 
respectively, p = 0, 0073). 
In the daily analysis, we found less accuracy on the first day after insertion for 
both sensors. The performance of the DG5M remained stable during the 7 days 
of life, while the accuracy of the FSL worsened over the last four days of use of 
its duration of 14 days (Table 8). 
 
 
 
Hospital phase 
 
During the hospital phase, overall accuracy was better for G5M than FSL with 
ARD of 10.7 (4.8-19.8) % vs 14.7 (7.3-27.4) %, p < 0.001. In the hypoglycemic 
range, both systems had similar performances, whereas in the hyperglycemia 
DG5M range it was better than FSL (7.6 [3.7-13.0] % vs 10.5 [5.8-16.5] %, p 
<0.001). In euglycemia DG5M, it was more accurate (ARD 13.2 [5.3-22.7] %) 
compared to FSL (20.1 [10.1-34.4] %) p <0.001. 
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Regarding the accuracy of the sensors at different rates of glycemic change, this 
was only possible in the hospital phase. The DG5M sensor was more accurate 
when blood glucose was stable (-0.5 <ROC <0. 5 mg / dl / min) with an ARD of 
10.6 (4.8-15.2) % compared to 13.3 (6.6-26.2) %, of the FSL, p <0.001). The 
DG5M sensor demonstrated better performance than FSL when glucose 
increased, both slowly and rapidly (0.5 mg / dL / min <ROC 1.5 mg / dL / min 
and ROC> 1.5 mg / dL / min) with ARD 8.7 (4.0-13.5) % compared to 11.5 (7.0-
23.6)%, p <0.001 and 14.7 (7.0-26.4)% compared to 17.3 (8.0-34.1)%, p <0.001, 
respectively. No differences in accuracy were observed when glucose levels 
decreased rapidly. 
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Metric, (unit) DG5M vs 
YSI 
FSL vs YSI p-value DG5M vs 
SMBG 
FSL vs 
SMBG 
p-
value 
Data pairs, (n) 
Overall 
Hypoglycemia* 
Euglycemia   
Hyperglycemia 
669 
78 
349 
242 
669 
78 
349 
242 
 1491 
162 
940 
389 
1929 
147 
1219 
563 
 
ARD, (%)       
Overall 
Hypoglycemia 
Euglycemia 
Hyperglycemia 
10.7[4.9-19.8] 
16.4[10.2-8.0] 
13.2[5.3-22.7] 
7.6[3.7-13.0] 
 
14.7[7.4-27.4] 
15.4[7.4-23.4] 
20.1[10.1-34.4] 
10.5[5.8-16.5] 
 
<0.001 
0.229 
<0.001 
<0.001 
9.8[4.7-18.0] 
14.0[7.7-23.2] 
9.7[4.7-18.4] 
8.5[4.3-13.9] 
 
12.3[5.6-21.4] 
13.7[7.4-23.9] 
13.1[6.2-23.7] 
10.2[4.5-16.8] 
 
<0.001 
0.8468 
<0.001 
0.0073 
ARD (%) during different days 
Day 1 
Day 2 
Day 3 
Day 4 
Day 5 
Day 6 
Day 7 
Day 8+ 
Day 9 
Day 10 
Day 11 
Day 12 
Day 13 
Day 14 
   10.9[5.8-18.9] 
10.4[5.7-18.8] 
9.9[4.6-20.5] 
11.2[5.6-19.8] 
9.4[4.4-13.8] 
8.0[3.8-16.8] 
8.8[2.9-16.5] 
14.1[5.7-23.8] 
8.9[4.5-15.1] 
7.1[4.4-12.9] 
10.0[5.7-16.5] 
8.0[3.5-16.7] 
10.4[5.0-18.5] 
9.2[3.9-11.1] 
14.5[7.1-23.9] 
12.0[6.4-21.7] 
11.2[5.0-23.7] 
12.7[5.1-22.2] 
12.5[5.2-19.7] 
10.7[4.4-20.1] 
11.9[4.4-20.3] 
11.5[5.1-20.6] 
12.4[4.5-21.4] 
10.4[3.8-18.4] 
13.7[6.8-22.1] 
12.9[7.0-23.1] 
13.5[7.3-20.8] 
13.2[8.6-20.9] 
0.0427 
0.1088 
0.1984 
0.4692 
0.0207 
0.1972 
0.0640 
0.1589 
0.0374 
0.1364 
0.0478 
0.0067 
0.0947 
<0.001 
ISO 15197:2013 (§) 
Overall 
Hypoglycemia 
Euglycemia 
Hyperglycemia 
69.1 
67.5 
61.0 
81.4 
54.4 
76.6 
41.0 
67.4 
 72.2 
78.4 
69.0 
78.2 
62.9 
76.9 
58.6 
69.1 
 
CEG-Zone A, (%) 
Overall 
Hypoglycemia 
Euglycemia 
Hyperglycemia 
78.9 
85.9 
70.8 
88.4 
66.1 
96.2 
50.1 
79.3 
 82.2 
90.7 
78.5 
87.7 
74.7 
97.3 
67.9 
83.5 
 
CEG-Zones A+B, (%) 
Overall 97.9 98.2  98.6 99.0  
Hypoglycemia 85.9 96.2  90.7 97.3  
Euglycemia 100 100  99.6 99.7  
Hyperglycemia 98.8 96.3  99.5 97.9  
 
 
 
YSI: Yellow Springs *Hypoglycaemia: <3.9 mmol/L (<70 mg/dl); euglycaemia 3-9-10 
mmol/L (70-180 mg/dl); hyperglycaemia > 10 mmol/L (>180 mg/dl); +Corresponds to day 1 
after insertion of G5 sensor; § Performance of the sensor stability was assessed by calculating 
the percentage of system readings within ±0.83 mmol/L (±15 mg/dL) for values <5.55 mmol/L 
(<100 mg/dL)  or ±15% for values ≥5.55 mmol/L (≥100 mg/dL).  
  
Table 8. ALL PAIRS ANALYSIS. Accuracy metrics are computed on all CGM-YSI and 
CGM-SMBG data pairs available. Median[25th-75th] percentile and mean(sd) are reported for 
non-normally distributed metrics and for normally distributed metrics, respectively.[46] 
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Safety and adverse events  
No sensor failures that require removal or infection at the insertion site have 
been reported. 
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DISCUSSION AND CONCLUSION 
 
These studies compared three CGM systems: the FreeStyleLibre, the Dexcom 
G4 Platinum and the Dexcom G5 Mobile during at home use and during induced 
glycemic excursions, in a hospital phase. It is important to underline that the 
system compared are not equivalent, since FreeStyleLibre and Dexcom G5M 
can be used in placed of SMBG for insulin adjustments, while Dexcom G4P is 
just considered adjunctive to SMBG. Another important difference is the MSL 
that is of 14 days for Libre and 7 days for Dexcom G4P and G5M.  
Although these differences for us it was important to compare the systems 
because they are widely used in Italy and because these results are very 
important such we are approaching a turning point in which the accuracy of 
different CGM sensors has improved rapidly. This will enhance CGM 
integration with insulin infusion pumps including both low threshold and 
predictive low blood glucose suspension (available now), as well as hybrid and 
fully automated closed-loop systems using insulin or insulin and glucagon.  
 
In the first study, we evaluated the accuracy of the Dexcom G4P over 7 days 
manufacturer-specified lifetime (MSL), as many patients use this procedure to 
avoid the inconvenience of weekly sensor changes, and to reduce costs. In our 
support, there is a recent study which has shown that the accuracy of DG4P 
remains unchanged a week over MSL [44]. We have noticed, in fact, that the 
Dexcom G4P has better accuracy in the 2 weeks in the euglycemic range, and 
this is probably due to the 2 daily calibrations. 
The accuracy of FSL decreased between days 11 and 14:  an important finding 
considering that some patients use this sensor as a substitute for the SMBG in 
all days of use. While for Dexcom G4P the accuracy lower in days 1 and 8 as 
expected, CGM accuracy on day 1 is known to be worse than performance on 
subsequent days, this could be related to sensor recalibration. 
Comparing week 1 and week 2 no differences were noted with the two systems 
(in hospital phase and at home). The accuracy of both CGM was worse during 
rapid glucose change probably due to lag time between plasma and interstitial 
fluid [47]. MARD of both systems reached about 20% in hypoglycemic range 
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during home phase, this confirmed that low glucose reading have to be checked 
by SMBG. 
In hospital phase, during the first week, FSL and DG4P had similar accuracy 
across all glucose ranges, but FSL performed better for rapid glucose reductions 
> 1.5 mg / dl / min (> 0.08 mmol /l). Whereas, in the second week, FSL was 
more precise than DG4P in the hyperglycemic range and when blood glucose 
levels increased > 0.5 mg / dl / min (0.03 <ROC <0.03 mmol / L). 
Aberer et al. evaluated FSL compared to DG4P and Medtronic Enlite for 12 
hours in a hospital environment, during which real life conditions were 
reproduced, such as meals, exercise, hypo and hyperglycaemia [48] reporting 
values concordant with ours. 
In our study, unlike, we wanted to test the accuracy in rapid glycemic changes 
by finding that FSL and DG4P were equally accurate when used within MSL 
and with glucose change rates of less than 1.5 mg / dl / min (<0,08 mmol/l/min). 
For higher rates of variation, as can happen after an insulin correction bolus, or 
during physical activity, FSL demonstrated to be more accurate. 
 
Comparing Dexcom G4P and Libre, we can conclude that in patients with good 
glycemic control, the two sensors are similar in accuracy, while FreeStyle Libre 
may be preferable in patients with high glycemic variability. We didn’t find any 
difference in the need of replace sensors or in lifetime. 
 
In the second study we compared Dexcom G5 Mobile vs FreeStyleLibre. 
Dexcom G5M utilized a new updated algorithm respect to DG4P (505 software). 
This study is very relevant also because these systems have been approved by 
U.S. Food and Drud administration (FDA), to replace finger stick blood glucose 
testing to make treatment decision, FSL for non adjunctive use in days 2-10, 
Dexcom G5M in days 1-7.  
In our study we noted that Dexcom G5M was stable in accuracy over all days of 
use, while FSL accuracy decreases between days 11 and 14, confirming the 
previous results. In home phase and in hospital phase, DG5M had better 
performance than FSL in euglycemic and hyperglycemic range.  
The G5M sensor demonstrated better performance than FSL during rapid 
glucose increase, no differences in accuracy during rapid glucose decrease. 
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Both sensors had similar accuracy in hypoglycemic range.  
 
The principals limits of these studies are the short duration and the fact that the 
glycemic values at home have been measured by the patients themselves. 
A further limitation is also linked to the fact that in the first study, we used the 
BG meter inside FSL, while in the second, we used the Aviva Accu Check 
glucometer. The factory pre-calibration may have been designed and / or 
optimized in order to better match the SMBG collected with the FSL meter. 
However, despite these considerations, when we used an independent system 
YSI, the results emerged in agreement. 
It would be interesting to evaluate the difference in terms of accuracy between 
Dexcom G5M and the new 90-day implantable Eversense sensor that uses a 
different methodology (fluorescence). This is part of our future prospects. 
 
In conclusion, our data shows that 2-week Dexcom G4P at home has similar 
accuracy as Freestyle Libre regardless of MSL. During rapid swings of glucose 
levels, FSL and DG4P are similarly accurate when used within MSL, and when 
glucose changes less than 1.5 mg / dl / min (0.08 mmol / L). Above this rate of 
change, FSL is more accurate. Dexcom G5M is more accurate than FSL across 
all glucose value, except in hypoglycemia and during rapid glucose decreases. 
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